Horizon Kinetics Asset Management LLC Sells 141 Shares of Amgen Inc. (NASDAQ:AMGN)

Horizon Kinetics Asset Management LLC reduced its stake in Amgen Inc. (NASDAQ:AMGN) by 3.9% during the third quarter, Holdings Channel.com reports. The firm owned 3,456 shares of the medical research company’s stock after selling 141 shares during the quarter. Horizon Kinetics Asset Management LLC’s holdings in Amgen were worth $1,114,000 as of its most recent filing with the SEC.

Several other institutional investors have also recently made changes to their positions in AMGN. Meyer Handelman Co. boosted its stake in shares of Amgen by 7.2% in the second quarter. Meyer Handelman Co. now owns 129,831 shares of the medical research company’s stock worth $40,566,000 after acquiring an additional 8,700 shares during the period. First Horizon Advisors Inc. boosted its stake in Amgen by 3.2% in the 3rd quarter. First Horizon Advisors Inc. now owns 60,769 shares of the medical research company’s stock worth $19,581,000 after purchasing an additional 1,872 shares during the period. Swiss National Bank grew its holdings in Amgen by 0.3% during the 3rd quarter. Swiss National Bank now owns 1,592,233 shares of the medical research company’s stock valued at $513,033,000 after buying an additional 5,500 shares in the last quarter. Napa Wealth Management bought a new stake in shares of Amgen during the third quarter valued at approximately $1,104,000. Finally, Second Half Financial Partners LLC bought a new position in shares of Amgen during the 3rd quarter valued at about $3,413,000. Institutional investors own 76.50% of the company’s stock.

Analyst Ratings Changes

AMGN has been the topic of several analyst reports. Oppenheimer reissued an “outperform” rating and set a $380.00 price objective on shares of Amgen in a research note on Wednesday, August 7th. William Blair reissued an “outperform” rating on shares of Amgen in a research report on Tuesday, November 12th. TD Cowen raised their price target on Amgen from $381.00 to $383.00 and gave the stock a “buy” rating in a research report on Monday, October 21st. Wolfe Research initiated coverage on shares of Amgen in a research report on Friday, November 15th. They set a “peer perform” rating on the stock. Finally, StockNews.com raised shares of Amgen from a “buy” rating to a “strong-buy” rating in a research note on Friday, November 1st. One equities research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating, eleven have issued a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, Amgen presently has a consensus rating of “Moderate Buy” and a consensus price target of $333.57.

Amgen Stock Down 0.2 %

Shares of NASDAQ AMGN opened at $294.00 on Tuesday. The company has a current ratio of 1.32, a quick ratio of 0.96 and a debt-to-equity ratio of 7.55. The stock has a market capitalization of $158.03 billion, a PE ratio of 37.64, a price-to-earnings-growth ratio of 2.63 and a beta of 0.60. Amgen Inc. has a 12-month low of $260.68 and a 12-month high of $346.85. The stock’s fifty day simple moving average is $315.69 and its two-hundred day simple moving average is $318.05.

Amgen (NASDAQ:AMGN) last announced its earnings results on Wednesday, October 30th. The medical research company reported $5.58 earnings per share for the quarter, beating the consensus estimate of $5.11 by $0.47. Amgen had a net margin of 13.00% and a return on equity of 168.35%. The company had revenue of $8.50 billion during the quarter, compared to the consensus estimate of $8.50 billion. During the same period last year, the firm earned $4.96 earnings per share. Amgen’s revenue was up 23.2% compared to the same quarter last year. As a group, analysts expect that Amgen Inc. will post 19.52 EPS for the current fiscal year.

Amgen Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, December 9th. Shareholders of record on Monday, November 18th will be given a dividend of $2.25 per share. This represents a $9.00 annualized dividend and a yield of 3.06%. The ex-dividend date of this dividend is Monday, November 18th. Amgen’s dividend payout ratio is presently 115.24%.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.